246 related articles for article (PubMed ID: 15984900)
41. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
Okarvi SM
Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
[TBL] [Abstract][Full Text] [Related]
42. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
43. Preclinical and clinical studies of peptide receptor radionuclide therapy.
Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
45. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
46. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
47. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
[TBL] [Abstract][Full Text] [Related]
48. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
49. The Influence of Different Spacers on Biological Profile of Peptide Radiopharmaceuticals for Diagnosis and Therapy of Human Cancers.
Farahani AM; Maleki F; Sadeghzadeh N
Anticancer Agents Med Chem; 2020; 20(4):402-416. PubMed ID: 31889492
[TBL] [Abstract][Full Text] [Related]
50. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
51. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
Rodrigues M; Traub-Weidinger T; Leimer M; Li S; Andreae F; Angelberger P; Dudczak R; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
[TBL] [Abstract][Full Text] [Related]
52. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
53. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.
De K; Banerjee I; Misra M
Amino Acids; 2015 Jun; 47(6):1135-53. PubMed ID: 25743164
[TBL] [Abstract][Full Text] [Related]
54. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
55. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.
McStay MK; Maudgil D; Williams M; Tibballs JM; Watkinson AF; Caplin ME; Buscombe JR
Radiology; 2005 Nov; 237(2):718-26. PubMed ID: 16192318
[TBL] [Abstract][Full Text] [Related]
56. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
McCarthy KE; Woltering EA; Anthony LB
Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
[TBL] [Abstract][Full Text] [Related]
57. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
58. An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases.
Tornesello AL; Tornesello ML; Buonaguro FM
Mini Rev Med Chem; 2017; 17(9):758-770. PubMed ID: 28117023
[TBL] [Abstract][Full Text] [Related]
59. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
[TBL] [Abstract][Full Text] [Related]
60. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
Melo IB; Ueda LT; Araujo EB; Muramoto E; Barboz MF; Mengatti J; Buchpiguel CA; Silva CP
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):31-6. PubMed ID: 20525456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
